Smoking levels remain unchanged in Wales at 19%

Smoking levels remain unchanged in Wales at 19%

June 22 2018 A downward trend in the proportion of adults smoking has stalled at 19%, the annual...

Measles outbreaks prompt reminder about MMR vaccination before holiday travel

Measles outbreaks prompt reminder about MMR vaccination before holiday travel

June 22 2018 Young people should ensure they have had both doses of the MMR vaccine, especially...

Dementia risk advice introduced into NHS Health Check

Dementia risk advice introduced into NHS Health Check

June 19 2018 Health professionals providing the NHS Health Check service will be expected to give...

CCA launches valproate safety audit for pharmacy

CCA launches valproate safety audit for pharmacy

June 19 2018 A practice-based audit will seek to explore community pharmacy’s contribution...

Independent review backs pharmacy smoking cessation services in Wales

Independent review backs pharmacy smoking cessation services in Wales

June 15 2018 Smoking cessation services provided by pharmacies in Wales are “effective and...

  • Smoking levels remain unchanged in Wales at 19%

    Smoking levels remain unchanged in Wales at 19%

    Friday, 22 June 2018 14:54
  • Measles outbreaks prompt reminder about MMR vaccination before holiday travel

    Measles outbreaks prompt reminder about MMR vaccination before holiday travel

    Friday, 22 June 2018 14:48
  • Dementia risk advice introduced into NHS Health Check

    Dementia risk advice introduced into NHS Health Check

    Tuesday, 19 June 2018 10:04
  • CCA launches valproate safety audit for pharmacy

    CCA launches valproate safety audit for pharmacy

    Tuesday, 19 June 2018 09:58
  • Independent review backs pharmacy smoking cessation services in Wales

    Independent review backs pharmacy smoking cessation services in Wales

    Friday, 15 June 2018 18:16

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageJanuary 10 2018

The medicines regulator has highlighted the different strengths of co-dydramol in its latest Drug Safety Update. 

For many years co-dydramol has been available at a fixed ratio of 1:50, combining dihydrocodeine 10mg and paracetamol 500mg. However, the MHRA’s latest DSU is advising that new strengths containing greater amounts of dihydrocodeine – co-dydramol 20/500 mg and co-dydramol 30/500 mg tablets – are becoming available.

Health professionals should take care to ensure the intended strength is clearly prescribed and the correct strength is dispensed, says the MHRA. If the prescribed strength is unclear, the person dispensing should contact the prescriber for clarification. It is also asking that health professionals “report suspected adverse drug reactions with opioids, including any harm from medication error, via the Yellow Card Scheme.”

The January 6 DSU newsletter also asks health professionals to ask if a patient has been using herbal medicines when reporting any suspected adverse drug reaction. If herbal medicines or traditional Chinese medicines have been used, this information should be included on the Yellow Card scheme report.

Ideally, information about a herbal product should include the brand name, the list of ingredients, a copy of the package labelling if available, and any manufacturer details. Patients should also be advised to check for the Traditional Herbal Registration Certification Mark.

Another medicine included in the DSU newsletter is daclizumab (daclizumab beta), which is “now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least two other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable.”

The MHRA is advising that patients with pre-existing hepatic disease or hepatic impairment should not use daclizumab. Caution should also be taken in prescribing daclizumab “in patients receiving other medication that may be hepatotoxic, including over-the-counter products and herbal medicines.”

Links:
MHRA Drug Safety Update: monthly PDF newsletters        
MHRA Drug Safety Update: monthly PDF newsletter. January 6 2018. 11;6.                 
Co-dydramol DSU             
Herbal medicines DSU    
Daclizumab DSU                

Practice News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 19 2018 A practice-based audit will seek to explore community pharmacy’s contribution in supporting girls and women of childbearing potential who need to take valproate medicines. Launched by...